Agile Therapeutics Inc. (NASDAQ:AGRX) saw strong trading volume on Wednesday . 58,735 shares were traded during mid-day trading, a decline of 9% from the previous session’s volume of 64,402 shares.The stock last traded at $6.65 and had previously closed at $6.58.

A number of equities research analysts have commented on the stock. FBR & Co reissued a “buy” rating on shares of Agile Therapeutics in a research report on Thursday, June 2nd. Cantor Fitzgerald restated a “buy” rating on shares of Agile Therapeutics in a report on Tuesday, May 31st. Noble Financial restated a “buy” rating and issued a $15.00 target price on shares of Agile Therapeutics in a report on Friday, July 8th. Finally, Zacks Investment Research cut shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $15.00.

The firm’s market capitalization is $196.60 million. The firm has a 50 day moving average price of $7.40 and a 200 day moving average price of $6.70.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.11. On average, equities analysts forecast that Agile Therapeutics Inc. will post ($1.12) earnings per share for the current year.

An institutional investor recently raised its position in Agile Therapeutics stock. Marshall Wace LLP raised its position in shares of Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 at the end of the most recent reporting period.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.